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DSCCaveolin-1 is a major structural protein of caveolae and speciﬁcally binds cholesterol (Chol). The caveolin
scaffolding domain is thought to be involved in caveolin–Chol interaction through the sequence V94-T-K-Y-W-
F-Y-R101, a motif that matches a cholesterol recognition amino-acid consensus (CRAC). In the present work,
three CRAC-containing peptides, corresponding to caveolin-1 94–101, 82–101 and 93–126, were tested to
study the role of the CRAC motif in the caveolin–Chol interaction in 1,2-dipalmitoyl-sn-glycero-3-
phosphocholine (DPPC) bilayers using differential scanning calorimetry (DSC), ﬂuorescence and circular
dichroism (CD). The Y97I substituents of the three peptides and one peptide segment corresponding to
caveolin-1 101–126 that excludes the CRACmotifwere also tested for comparison.Our results showed the poten-
cy of these CRAC-containing peptides in sequestering Chol into domains and the enhanced role of the
intramembrane domain and scaffolding domain for the potency. Of the three CRAC-containing peptides, the pep-
tide 93–126 was particularly effective in promoting Chol segregation, while the peptide 82–101 was less potent
in promoting the formation of domains than the peptide 93–126, but wasmore potent than the peptide 94–101.
The domain partition of DPPC/Chol bilayerswas not observed in the presence of the peptide 101–126, in contrast
to the case in the presence of the peptide 93–126 at the same concentrations of peptide and Chol. The potency of
the CRACmotif in Chol segregationwas lowered by the Y97Imutation. The difference in structuremay be a factor
that contributes to different effects of these peptides on the distribution of Chol in the lipid membrane.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Caveolae are 50–100 nm ﬂask-shaped invaginations of the plasma
membranes of most mammalian cells including endothelial cells,
macrophages, dendritic cells and adipocytes [1,2]. Caveolins have been
identiﬁed as integral membrane proteins and an important structural
component of caveolae [3]. The caveolin protein family has three mem-
bers, caveolin-1, -2, and -3 [4]. Caveolin-1 is the prototypical caveolin
familymember and is therefore themostwidely studied of itsmembers.
Caveolin-1 is a 22-kDa protein of 178 amino acids and plays a central
role in the formation and function of caveolae [5]. Functional studies
have shown that caveolin-1 is involved in a wide range of cellular pro-
cesses, including cell cycle regulation, signal transduction, endocytosis,
and cholesterol (Chol) trafﬁcking and efﬂux [2,6–11]. Although the
role of caveolin-1 in regulating signallingmolecules is largely unknown,
it has been suggested that caveolin-1 may function as a scaffolding pro-
tein to organize and concentrate signalling molecules within caveolaeSupramolecular Structure and
un 130012, PR China. Tel.: +86[12]. Many signalling molecules, such as epidermal growth factor
(EGF) receptor, platelet-derived growth factor (PDGF) receptor, estro-
gen receptor, H-Ras, and ERK-1/2, have been found to localize in caveo-
lae and interact with caveolin-1 [13–15]. In addition, some enzymes
with fundamental vascular functions, such as endothelial nitric oxide
synthase (eNOS) and prostacyclin synthase (PGIS), have also been
found to be bound to caveolin-1 within caveolae [16–19].
A series of biochemical results have led to a consensus topological
model of caveolin-1 although no direct structural information is avail-
able [5,20]. Caveolin-1 contains cytoplasmic N- and C-terminal domains
that sandwich the membrane-association domains including residues
82–101 (the caveolin scaffolding domain, CSD), residues 102–134 (the
intramembrane domain, IMD) and residues 135–150 [17]. The IMD is
proposed to form a unique α-helical hairpin that does not completely
traverse the membrane [20–22]. Despite inserting into membranes,
the IMD was not found to be essential for membrane binding. Rather,
two domains adjacent to the IMD, residues 82–101 and 135–150 were
found to be largely responsible for high afﬁnity binding to membranes
[23–25]. The CSD was suggested to be essential for both caveolin-1 olig-
omerization and for the interactions of caveolin-1 with other proteins
[26]. Associations with other proteins through the CSD may help the
coordination of the proteins with receptors and efﬁcient signal
Fig. 1. Schematic representation of the domains of caveolin-1 and the amino acid se-
quences of the peptide segments of interest in this study.
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transduction through caveolin–protein interactions at the caveolae in a
recent study [29]. Furthermore, mutational studies clearly indicate that
CSD is necessary and sufﬁcient for membrane attachment [24]. It has
been observed that caveolin-1 truncation mutants that retain the com-
plete N-terminus and the scaffolding domain (caveolin-1 1–101) but
lack the intramembranedomain and the palmitoylated C-terminus tight-
ly bind the membrane and target to caveolae. In contrast, caveolin-1
truncationmutants lacking the CSDwere found to be completely soluble
[25]. Therefore, the CSD seems to be an essential domain for multiple
properties of the caveolin-1 molecule. Recent studies on the structures
of these caveolin functional segments in various environments including
aqueous solutions, micelles and phospholipids conﬁrmed that the IMD
relevant segments adopt a helix–break–helix structure and that Pro110
is a key residue for the formation of the helical hairpin structure [30–32],
while the CSD relevant segments are β-strand structured [33,34].
Caveolae are enriched with Chol and glycosphingolipids. The
binding of caveolin-1 to Chol was found to be tight and speciﬁc [35,
36]. Caveolin-1 plays an important role in cellular Chol homeostasis, a
process that controls intracellular lipid composition and prevents Chol
accumulation [37]. It was demonstrated that a dominant-negative
caveolin-1 mutant causes intracellular retention of free Chol and a de-
crease in Chol synthesis as well as efﬂux of Chol from the cell [38].
Caveolin-1 inserts into membranes of phosphatidylcholine in a Chol-
dependent manner [36]. Caveolae are also enriched with saturated
fatty acids, mainly palmitic acid C16:0 and stearic acid C18:0, which
account for more than 50% of total fatty acids (the other main composi-
tion in caveolae is oleic acid) [39–42]. This is quite different from the fatty
acid compositions inwhole cells.Moreover, palmitic acid and stearic acid
are the main fatty acids binding to caveolin-1. However, the acylation or
palmitoylation of caveolin-1 is not necessarily required for Chol binding,
although it may affect the Chol binding of caveolin-1 [43,44]. When the
three palmitoylation sites are mutated, the resulting protein is still
translocated to caveolae [45], and the palmitoylation-deﬁcient
caveolin-1 mutant is still responsive to Chol-induced stabilization at
levels that are virtually identical to those obtained with wild-type
caveolin-1 [46]. This suggests that segments of the protein itself facilitate
the interaction of caveolin-1 with Chol-rich domains.
The CSD of caveolin-1 contains a consensus sequence -L/V-(X)(1–
5)-Y-(X)(1–5)-R/K- in which (X)(1–5) represents one to ﬁve residues
of any amino acid. The consensus sequence has been found in several
proteins that interact with Chol and is referred to as the Chol recogni-
tion amino-acid consensus (CRAC) [47,48]. The CRAC motif in CSD cor-
responds to residues 94–101 with the sequence VTKYWFYR that was
suggested to anchor at the membrane interface as an α-helical confor-
mation [49]. Although mutational analysis of the 20-amino-acid CSD
domain identiﬁed a short membrane attachment sequence KYWFYR
that is sufﬁcient to localize a cytoplasmic green ﬂuorescent protein
(GFP) to the membrane, the entire CSD is necessary for caveolar
membrane targeting [50]. Previous studies using the model membrane
1-stearoyl-2-oleoyl-sn-glycero-3-phosphocholine (SOPC) also showed
that the KYWFYR sequence does not sequester Chol into domains and
has no preferential interaction with Chol, but the CRAC sequence
VTKYWFYR does [51,52], further indicating the importance of the
CRAC in interactions with Chol.
In order to gain further insight into the role of the CRAC in sequester-
ing Chol into domains, we characterized the interactions of the
caveolin-1 intramembrane hydrophobic segment alone (ranging over
101–126) and that ﬂanked by the CRAC motif (ranging over 93–126)
withmodelmembrane in this study using differential scanning calorim-
etry (DSC), ﬂuorescence, and circular dichroism (CD) techniques. We
also characterized the interactions of the caveolin-1 CRAC sequence
(ranging over 94–101) and CSD segment (ranging over 82–101) with
the model membrane and compared the results with those of the
intramembranepeptides, bywhich the roles of the caveolin-1 scaffolding
and intramembrane hydrophobic segments in inducing redistribution ofChol in the lipid membrane could be explored. In the CRAC motif se-
quence of caveolin-1, each of three motif-determining residues V94,
Y97, and R101 may play a speciﬁc role in the interactions of peptides
with Chol. The important role of V94 in interactions of the CRAC motif
with Chol was implicated in previous studies that revealed a difference
between the KYWFYR and VTKYWFYR sequences in promoting the for-
mation of the Chol domain, as mentioned above [51,52]. In the present
study, we focused on another motif-determining residue Y97. The
tyrosine side chain has a polar OH group and an aromatic ring that are
supposed to facilitate interaction with the interfacial ring component of
Chol. Therefore, we substituted the Y97 residue of all the CRAC-
containing peptides with a residue with an alkyl side chain, isoleucine
(Ile). It is expected that the hydrophobic residue Ile could insert into
the membrane more deeply than the polar residue tyrosine, by which
the orientation and local structure of the CRAC fragment in the mem-
brane could be changed and thus the interaction of the CRAC segment
with Chol could be affected. The lipid 1,2-dipalmitoyl-sn-glycero-3-
phosphocholine (DPPC) was used as a model membrane in this study
for two reasons: 1) saturated fatty acids (16:0 and 18:0) are the main
component and main caveolin-1 binding species in caveolae, and DPPC
is a saturated lipid with 16 carbon atoms in each hydrocarbon chain;
and 2) the mixture of DPPC with even relatively small amount of Chol
can result in Chol-rich and Chol-poor domains and these domains
display distinct phase transition temperatures in DSC analysis of speciﬁc
temperature ranges when using water-based solvents, and thus, the
redistribution of both Chol and lipids induced by peptides in the mem-
brane mixture can be easily monitored by the change in endotherms.
2. Materials and methods
2.1. Materials
The peptides from human caveolin-1 94–101, 82–101, 93–126 and
101–126, referred to as Cav-1(94–101), Cav-1(82–101), Cav-1(93–
126) and Cav-1(101–126), respectively, and the Y97I substituents of
the ﬁrst three peptides, referred to as Cav-1(94–101/Y97I), Cav-1(82–
101/Y97I), and Cav-1(93–126/Y97I), were used in this study (Fig. 1).
The peptides were synthesized and puriﬁed by GL Biochem (Shanghai)
Ltd and Shanghai Apeptide Co., Ltd (Shanghai, China). Three lysine (Lys)
residues were added on each terminal end of the two 93–126 peptides
[Cav-1(93–126) and Cav-1(93–126/Y97I)], while two Lys residueswere
added in theN-terminus and three Lys residues added in the C-terminus
of the Cav-1(101–126) peptide, in order to increase the solubility of the
peptides in the puriﬁcation. Previous studies have demonstrated that
tagging hydrophobic peptides with Lys residues does not affect the
native characteristics of the peptides inserting in membrane mimetic
environments and folding as anα-helical structure, and evenoligomeric
states ([53] and the references therein). The purity was assessed by
high-performance liquid chromatography (HPLC) andmass spectrosco-
py and was found to be greater than 95%. The phospholipid DPPC was
Fig. 2. DSC thermograms of DPPC alone and DPPC with 15 mol% and 20 mol% Chol.
2590 G. Yang et al. / Biochimica et Biophysica Acta 1838 (2014) 2588–2599purchased from Avanti Polar Lipid, Inc. (Alabaster, AL, USA). Chol was
obtained from Sigma-Aldrich (St. Louis, MO, USA). The organic solvent
1,1,1,3,3,3-hexaﬂuoro-2-propanol (HFIP, 99.5%) was purchased from
Acros Organics (Morris Plains, NJ, USA). All chemicalswere used directly
after purchase without further puriﬁcation.
2.2. Sample preparation
Phospholipid DPPC and Chol were separately dissolved in a mixture
of chloroform and methanol (2:1 v/v). The peptide powder was
dissolved in HFIP solvent to prepare a stock solution. An appropriate
volume of peptide stock solution was mixed with the chloroform/
methanol co-solvent of DPPC and Chol or DPPC alone. The solvents
were then evaporated under a stream of nitrogen to deposit a uniform
ﬁlm of lipid over the bottom of the tube. The obtained lipid ﬁlm was
kept under vacuum overnight to remove residual organic solvents.
The dried lipid ﬁlm was hydrated using 10 mM Na2HPO4/NaH2PO4
buffer containing 100 mM NaCl at pH 7.4. The lipid ﬁlm together with
the buffer was mixed by vortexing for several seconds. The vesicle
suspension was then sonicated using a bath-type sonicator for at least
60 min with caution taken to ensure that the temperature was
maintained at 10 °C above the phase transition temperature of the
lipids. The small unilamellar lipid vesicles (SUVs) were obtained and
used immediately after preparation. The corresponding blank samples
without peptides were also prepared using the same methods.
2.3. Fluorescence experiments
Fluorescence measurements were performed using an RF-5301PC
spectroﬂuorophotometer at room temperature. The parameters used
for the emission spectra were as follows: scan range, 290–500 nm; ex-
citation, 280 nm; excitation slit, 5 nm; emission slit, 5 nm; and scan
rate, medium. Each spectrum was recorded after the average of three
scans and the background spectrum was subtracted. For acrylamide
quenching experiments, an aliquot of acrylamide from a stock solution
of 1 M acrylamide dissolved in buffer was added to the sample solution
and the ﬂuorescence spectra were measured. The quenching constant
Ksv was determined by the Stern–Volmer equation:
F0=F ¼ 1þ Ksv Q½  ð1Þ
where F0 and F are the ﬂuorescence intensity in the absence and pres-
ence of the quencher (Q), respectively. The samples of 4 μMpeptides in-
corporated with 0.5mM lipids (P:L 1:125)were used in all ﬂuorescence
measurements.
2.4. Differential scanning calorimetry (DSC) measurements
DSC measurements were performed using a Microcal VP-DSC calo-
rimeter (MicroCal, Inc., Northampton, MA, USA) immediately after the
preparation of the samples. A 0.5 mL liposome suspension incorporated
with peptide was placed in the sample cell and the same volume of
buffer was placed in the reference cell. All of the sampleswere degassed
for 10 min at room temperature prior to loading the cell. Samples were
heated at a rate of 0. 5 °C/min over a temperature range of 20–60 °C and
were equilibrated for 15 min at 20 °C before each scan. Blank experi-
ments with buffer on both cells were also performed for subsequent
baseline correction. The expected experimental errors in temperature
and enthalpy values were ±0.1 °C and ±5%, respectively. The
calorimetric cell was ﬁlled with 1.5 mM lipids and 18.75 μM peptides
(peptide-to-lipid mole ratio P:L = 1:80). The concentrations of 100 μM
were also used for Cav-1(94–101) and Cav-1(94–101/Y97I) (P:L =
1:15). The Chol composition was varied from 0 to 20% in mole fraction.
Buffer subtraction and baseline correction were performed using
Microcal Origin software (MicroCal, Northampton, MA, USA). The DSC
proﬁles were analysed by decomposition of the main transition peaksinto two individual components with Lorenz lineshape and ﬁtted as
the sum of the components using the non-linear least square curve
ﬁtting procedure supplied with the Origin 8.0 software.
2.5. Circular dichroism (CD) measurements
The CD spectra were recorded on a PMS-450 spectropolarimeter
(Biologic, France) at room temperature using a 0.5-mm path-length
quartz. Samples of 24 μM peptides and 3 mM lipids (P:L 1:125) were
used. Data were recorded from 190 to 260 nm at a speed of 0.1 nm/s.
The background signal was subtracted from all spectra. The intensities
of the ﬁnal spectra were expressed as mean residue ellipticity. The
secondary structure contents were estimated by the CDPro software
package using the programCONTIN/LL. A reference set of SMP56 includ-
ing 56 proteins was used in the analyses of CD data.
3. Results
3.1. Thermotropic phase behaviors of DPPC vesicles in the presence of Chol
The heating scan of pure DPPC showed two endothermic transitions
(Fig. 2). The broad one centred at 34.5 °C corresponds to the pre-
transition from a lamellar gel phase (Lβ′) to a rippled gel phase (Pβ′),
and the sharp one at 41.6 °C corresponds to the main transition from
the rippled gel phase to the liquid crystal phase (Lα) [54,55]. Upon in-
corporation of 15 mol% and 20 mol% Chol into the DPPC vesicles, the
pre-transition peaks were broadened or abolished and the main transi-
tion peaks display an obviously asymmetric broadening (Fig. 2). We
deconvolved the heat capacity proﬁles of the main transition peaks in
the presence of Chol into two components and obtained a sharper
peak that has a transition temperature lower than that of pure DPPC
and a broader peak that has a transition temperature higher than that
of pure DPPC. The parameters including the transition temperature,
cooperativity and melting enthalpy of each component (represented
by Tm(1),ΔT1/2(1), andΔH1 for the transition at lower transition temper-
ature, and Tm(2), ΔT1/2(2), and ΔH2 for the transition with higher transi-
tion temperature, respectively), and the total endothermic melting
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ﬁtting of the DSC endotherms (Table 1 and Fig. S1 in Supplementary
Materials). The component at Tm(1) is attributed to the Chol-poor
domain and the other component at Tm(2) is attributed to the Chol-
rich domain [56].
The addition ofmore quantities of Chol generatedmore perturbation
to the Chol-poor domain than to the Chol-rich domain, which ampliﬁed
the difference in the packing of lipid chains between the two domains
and, thus, caused a larger ΔTm. Moreover, a slightly larger percentage
ofΔH2 inΔHt (PΔH2 in Table 1) for 20mol%Chol also suggests somewhat
more perturbation of Chol to the Chol-poor domain than to the Chol-
rich domain.
Considering that the pre-transition peaks were not observed in the
presence of Chol, we focused only on the thermotropic phase behaviors
of the main transition peaks in the following sections.3.2. Thermotropic phase behaviors of DPPC vesicles mixed with peptides
94–101 and Chol
The incorporation of peptides Cav-1(94–101) and Cav-1(94–101/
Y97I) with DPPC vesicles gave rise to a small decrease in the main tran-
sition temperature Tm and a broadening of the peak width ΔT1/2 (or a
decrease in cooperativity) along with the broadening or vanishing of
the pre-transition peak. The endothermic melting enthalpy of the
DPPC vesicles was slightly affected by the two peptides (Fig. 3 and
Table 2). The addition of both 15 mol% and 20 mol% Chol in the
peptide-containing DPPC lipids at P:L of 1:80 resulted in a dramatic de-
crease both in cooperativity and enthalpy and a decrease in Tm of the
endothermic transition. When the ratio of P:L was increased to 1:15, a
distinct separation of the main transition peaks was observed and the
peak separation increased from 15 mol% Chol to 20 mol% Chol. Similar
to the results for peptide-free vesicles, a sharper peak at the lower tran-
sition temperature corresponding to the Chol-poor domain and a
broader peak at the higher transition temperature corresponding to
the Chol-rich domain were obtained by the two-component ﬁtting of
the thermograms of the DPPC/peptide/Chol mixed vesicles (Fig. S2 in
Supplementary Materials), and the thermotropic phase data of the
two components are listed in Table 2. In the presence of peptides, the
ΔHt of the DPPC vesicles also decreased with increasing mole faction
of Chol, which is consistent with the effect of Chol on pure DPPC
vesicles.
Despite similar thermotropic phase behavior, the liposomeswith the
wild-type peptide and its Y97I mutant displayed small but distinct dif-
ferences in ΔTm and PΔH2 of the phase transition, suggesting the differ-
ence of the two peptides in inducing distribution of Chol in DPPC
bilayers. The PΔH2, instead of ΔH2, was used to compare the difference
between the perturbations of Chol to lipid chains in the Chol-rich do-
main of DPPC bilayers with thewild-type peptide and Y97Imutant con-
sidering the different effects of the two peptides on the enthalpy of the
pure DPPCmembrane. Interestingly, the PΔH2 values of DPPC vesicles in
the presence of Cav-1(94–101)were smaller than those in the presence
of Cav-1(94–101/Y97I) at P:L 1:15, meaning that the phase transition of
the Chol-rich domain in the presence of the wild-type peptide requires
smaller fraction of enthalpy than it does in the presence of the Y97ITable 1
The phase transition data of DPPC vesicles with varying mole fractions of Chol.
Chol mol% Tm(1) °C ΔT1/2(1) °C ΔH1 kcal/mol Tm(2) °C
0a 41.6 1.1 6.1
15 40.3 1.4 3.2 42.2
20 40.1 3.3 2.5 42.3
a Themain phase transition of pure DPPC in DSC endotherm is a single peak. Thus Tm(1), ΔT1
those of the peak component at lower transition temperature. We list them like this just for simutant. This suggests that the packing of lipids in the Chol-rich domain
may be disturbed to a larger extent in the presence of the wild-type
peptide than in the presence of the mutant. It is likely that the lipids
were present in the Chol-rich domain in a smaller quantity in the
presence of the wild-type peptide than in the presence of the mutant.
In addition, ΔTm induced by the wild-type peptide was larger than
that induced by the mutant at 20 mol% Chol, further conﬁrming that
the larger difference in lipid packing between the Chol-rich and the
Chol-poor domains was induced by the wild-type peptide than the
mutant.
3.3. Thermotropic phase behaviors of DPPC vesicles mixed with peptides
82–101 and Chol
The DSC thermograms of DPPC vesicles incorporated with two
82–101 peptides at P:L 1:80 displayed a single main transition peak
with a broaderΔT1/2 and lower Tm than those of pure DPPC. Themelting
enthalpies of the main transitions were also lowered in the presence of
the peptides. The addition of 15 mol% Chol in the peptide-containing
DPPC vesicles further induced a decrease in cooperativity, Tm and ΔHt
of the main transition, but not peak separation. The peak separation
was observed in the DSC endotherms of the peptide-containing DPPC
vesicles only when the amount of Chol was increased to 20 mol%
(Fig. 4). Decomposition of the heat capacity proﬁles by two components
gave rise to a sharper peak at a lower Tm (Chol-poor domain) and a
broader peak at a higher Tm (Chol-rich domain), as shown in Fig. S3 in
the SupplementaryMaterials. A larger separation between the two tran-
sition components (larger ΔTm) and a smaller percentage of enthalpy
(smaller PΔH2) from the Chol-rich domain in the presence of Cav-
1(82–101) than in the presence of Cav-1(82–101/Y97I) were obtained
by ﬁtting of the DSC endotherm proﬁles of the DPPC/peptide/Chol ves-
icles (Table 3).
3.4. Thermotropic phase behaviors of DPPC vesicles mixed with peptides
93–126 and Chol
The DSC thermograms of DPPC vesicles containing two peptides 93–
126 also displayed a single main transition peak with a decreasing Tm
and an increasing ΔT1/2 with respect to pure DPPC. The ΔHt of the tran-
sition decreased in the presence of the Y97I mutant, while it slightly
changed in the presence of the wild-type peptide. With the addition of
both 15 mol% and 20 mol% Chol, an evident partition of the domain
was observed in the DSC thermograms of the peptide-containing
DPPC vesicles, and the partition was more pronounced with the in-
crease in Chol from 15 mol% to 20 mol% (Fig. 5). Decomposition of the
DSC endotherms demonstrated a general pattern of two peaks with
ΔT1/2(1) smaller than ΔT1/2(2) for the mixture of DPPC with peptides in
the presence of Chol except for the DPPC vesicles mixed with Cav-
1(93–126) and 15 mol% Chol which displayed the DSC endotherm of
two peak components with ΔT1/2(1) slightly larger than ΔT1/2(2)
(Fig. S4 in Supplementary Materials). Although the two peptides
exerted similar effects on the endothermic behaviors of the DPPC/Chol
bilayers, differences in PΔH2 and ΔTm, were still present, i.e., the ΔTm
values in the presence of the mutant were smaller than those in theΔT1/2(2) °C ΔH2 kcal/mol ΔHt kcal/mol ΔTm °C PΔH2%
6.1
2.3 1.0 4.2 1.9 24
3.4 0.9 3.4 2.2 27
/2(1) and ΔH1 of pure DPPC represent the Tm, ΔT1/2 and ΔHt of the single transition, but not
mplicity. The same expression is also used in Tables 2–4.
Fig. 3. DSC thermograms of DPPC vesicles incorporated with the peptides 94–101 (left: wild-type peptide; right: mutant) and various quantities of Chol.
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mutant were larger than those induced by the wild-type peptide
(Table 4).
3.5. The thermotropic phase behaviors of DPPC vesicles mixed with
Cav-1(101–126) and Chol
In contrast to the thermotropic behaviors of DPPC vesiclesmixedwith
Chol and the CRAC-containing peptide Cav-1(93–126), no observableTable 2
The phase transition data of DPPC vesicles with varying mole fractions of Chol in the presence
P:L Chol mol% Peptide Tm(1) °C ΔT1/2(1) °C ΔH1 kcal/mol T
1:80 0a Wildtype 41.0 2.0 6.3
Mutant 41.3 2.7 6.4
15a Wildtype 40.1 5.9 3.6
Mutant 40.7 5.5 4.8
20a Wildtype 40.3 6.1 2.9
Mutant 40.8 5.8 3.8
1:15 0a Wildtype 40.7 1.9 6.4
Mutant 41.0 1.7 8.5
15 Wildtype 38.7 1.3 1.8 4
Mutant 38.8 1.6 1.3 4
20 Wildtype 39.2 3.5 2.0 4
Mutant 39.4 2.6 1.9 4
a See the note in Table 1.separation of transition peak was detected in the DSC endotherms of
the DPPC vesicles mixed with Chol and the CRAC-removed peptide
Cav-1(101–126) at P:L 1:80, but a single transition peakwith an evident-
ly broadening line width and a decreasing transition temperature ap-
peared. The melting transition enthalpies of the lipid mixtures in the
presence of both 15 mol% and 20 mol% Chol were much smaller than
those were in the absence of Chol (Fig. 6 and Table 5). The perturbation
of the peptide to DPPC vesicles in the absence of Chol caused an increase
in both ΔHt and ΔT1/2 and a decrease in Tm with respect to pure DPPC.of peptides 94–101.









0.3 6.3 4.1 5.9 1.6 69
0.7 6.6 4.1 5.4 1.9 76
2.4 5.0 1.9 3.9 3.2 49
2.1 6.1 2.6 4.5 2.7 58
Fig. 4. DSC thermograms of DPPC vesicles incorporated with the peptides 82–101 (left: wild-type peptide; right: mutant) and various quantities of Chol.
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The ﬂuorescence spectra of the peptides incorporatedwith the DPPC
lipids including 50 mol% Chol and those of Chol-free vesicles are shown
in Fig. 7. The emission maxima were mostly unchanged following the
addition of Chol, remaining ﬁxed at ~342 nm and ~350 nm for
Cav-1(94–101) and Cav-1(94–101/Y97I), respectively, ~342–344 nm
for two 82–101 peptides, ~334 nm for two 93–126 peptides and
~339 nm for Cav-1(101–126). Previous studies have shown that the
ﬂuorescence emission at ~330 nm is related to a hydrophobic ambient
of tryptophan (Trp), while the ﬂuorescence emission at ~350 nm is
related to the exposure of the chromophore to a polar ambient [57].
Accordingly, the Trp residues of the intramembrane peptides could be
inserted in the membrane more deeply than the 82–101 and 94–101
peptides either in the absence or in the presence of Chol. The mixture
of 50mol% Chol with DPPC lipids resulted in a reduction in ﬂuorescence
intensity of the six CRAC-containing peptides. However, the magnitude
of the Chol-induced intensity reduction in the presence of thewild-type
peptides was different from that in the presence of the mutants. As
shown in Fig. 7, the ﬂuorescence intensities of the wild-type peptides
were higher than those of the mutant peptides in the absence of Chol,
while the intensities of the former were lower than [for Cav-1(94–
101) and Cav-1(82–101)] or close to [for Cav-1(93–126)] those of the
latter in the presence of Chol. The wild-type peptides displayed greater
decrease in the intensity than did themutants. It is noted that there areTable 3
The phase transition data of DPPC vesicles with varying mole fractions of Chol in the presence
Chol mol% Peptide Tm(1) °C ΔT1/2(1) °C ΔH1 kcal/mol Tm(2)
0a Wildtype 40.2 1.9 5.3
Mutant 40.1 2.4 5.9
15a Wildtype 38.1 2.8 4.8
Mutant 38.7 2.8 4.7
20 Wildtype 38.4 4.7 2.9 42.0
Mutant 36.9 3.2 1.7 40.0
a See the note in Table 1.two Trp residues on two 93–126 peptides, but only one ﬂuorescence
peak was observed, indicating that the two Trp residues were involved
in the same or very similar environment. The addition of 50 mol% Chol
in the DPPC vesicles with Cav-1(101–126) also caused a decrease in
ﬂuorescence intensity of the peptide. However, the magnitude of the
decrease in intensity was much smaller than those of two 93–126
peptides.
The effect of Chol on the position of the peptides in the membrane
was further characterized by the acrylamide quenching experiments
and the quenching constant Ksv that is associated with accessibility of
the quencher to Trp was obtained. As shown in Fig. 8 (also see
Figs. S5–S9 in Supplementary Materials), the Ksv values of the wild-
type peptides were smaller than those of the Y97I mutants were in
the absence of Chol, but contrasting results were obtained in the pres-
ence of Chol for all CRAC-containing peptides. Moreover, the Ksv values
of all peptides, either the wild-type peptides or the Y97I mutants, were
larger in thepresence of Chol than thosewere in the absence of Chol and
the Chol-induced changes in Ksv were larger in the presence of thewild-
type peptides than in the presence of the mutants.
3.7. Secondary structures of the peptides incorporated with the DPPC/Chol
vesicles
The secondary structures of the peptides incorporated with the DPPC
vesicles were monitored by Far-UV CD spectra in the absence andof peptides 82–101 at P:L 1:80.





5.6 1.0 3.9 3.6 26
5.0 1.3 3.0 3.1 44
Fig. 5. DSC thermograms of DPPC vesicles incorporated with the peptides 93–126 (left: wild-type peptide; right: mutant) and various quantities of Chol.
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strated a characteristic of disordered structure for two 94–101 peptides,
a substantial β-sheet structure for two 82–101 peptides and anα-helical
structure for two 93–126 peptides and the 101–126 peptide. With the
addition of 50 mol% Chol, a weak positive absorbance at ~ 231 nm
appeard for two 94–101 peptides. These absorbances may be associated
with the contribution of Trp98 [58]. The CD curves demonstrated a slight
decrease in the negative absorbance at ~ 218 nm for Cav-1(82–101), but
a slight increase in this absorbance for Cav-1(82–101/Y97I), in the pres-
ence of 50 mol% Chol. The presence of Chol also resulted in a slight de-
crease in the negative absorbances at ~ 210 nm and 222 nm for the
peptides 93–126. An obvious decrease in the intensity of thenegative ab-
sorbance was detected for Cav-1(101–126) with the addition of Chol.
The secondary structure contents of two scaffold peptides and three
intramembrane peptides in DPPC alone and in DPPC vesicles containing
50 mol% Chol were calculated based on the deconvolution of the CD
spectra and the results are listed in Table 6.
The secondary structures of the 93–126, 101–126 and 82–101 pep-
tides incorporated with the DPPC lipids were further estimated by the
attenuated total reﬂection Fourier transform infrared (ATR-FTIR)
spectra. The polarization-independent spectra that was obtained from
combination of the parallel and perpendicular polarized spectra of the
amide I region (1600–1700 cm−1) were analysed using curve ﬁtting
method and the secondary structure contents of the peptides in the
membrane were represented by the percentage of the area of theTable 4
The phase transition data of DPPC vesicles with varying mole fractions of Chol in the presence
Chol mol% Peptide Tm(1) °C ΔT1/2(1) °C ΔH1 kcal/mol Tm(2)
0a Wildtype 40.0 2.7 6.4
Mutant 40.4 2.0 5.0
15 Wildtype 38.6 4.8 3.0 41.6
Mutant 39.3 3.7 2.4 42.0
20 Wildtype 35.9 3.4 2.3 39.9
Mutant 38.5 3.5 1.2 41.7
a See the note in Table 1.speciﬁc secondary structure bands in the total band area. The experi-
mental details, the ATR-FTIR spectra, the band assignments and the sec-
ondary structure contents of the peptides are shown in the
Supplementary Materials (Figs. S10–S12, Tables S1 and S2). The typical
absorbance regions of the different secondary structure components
were assigned as follows: α-helix 1651–1657 cm−1, β-sheet 1609–
1636 cm−1 and 1684–1695 cm−1, β-turn 1662–1678 cm−1, and ran-
dom 1637–1646 cm−1 [59]. To avoid the perturbation of H2O absor-
bance, the lipid membranes used in the ATR-FTIR experiments were
hydrated byD2O, instead of the phosphate buffer thatwas used in CD ex-
periments. In addition, the peptideswere associatedwithﬂatmulti-layer
membranes in the ATR-FTIR experiments,while the peptideswere incor-
poratedwith SUVs in the CD experiments. The differences in experimen-
tal conditions could have certain effects on the data of the secondary
structures, nevertheless, the results obtained by the two methods were
comparable (See Tables 6 and S2 in Supplementary Materials).
4. Discussion
Caveolin-1 is a Chol-binding protein with an approximate 1:1 stoi-
chiometry in the presence of 0.2% sodiumdodecyl sulfate (SDS). Binding
of caveolin-1 to Chol is critical formaintenance of the caveolar structure
and protein function [3]. The segment consisting of the residues 94–101
with the VTKYWFYR sequence in the amino-terminal region of
caveolin-1 has been suggested to be a Chol recognition domain of theof peptides 93–126 at P:L 1:80.
°C ΔT1/2(2) °C ΔH2 kcal/mol ΔHt kcal/mol ΔTm °C PΔH2%
6.4
5.0
4.2 2.7 5.7 3.0 44
5.4 2.3 4.7 2.7 50
6.5 3.4 5.7 4.0 60
6.0 2.7 3.9 3.2 69
Fig. 6. DSC thermograms of DPPC vesicles incorporated with the peptides 101–126 and
various quantities of Chol.
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the hydrophobic segment comprising residues 105–125 that is sug-
gested to play a role in anchoring caveolin-1 to the membrane [22]. In
this study, we aimed to explore the role of the CRAC in sequestering
Chol into a domain and to evaluate the effects of the caveolin-1 scaffold-
ing and intramembrane hydrophobic segments on the CRAC activity in
Chol segregation. Thus, we selected in this study three CRAC-
containing peptides including residues 94–101 (CRAC motif), 82–101
(CSD segment), and 93–126 (CRAC-ﬂanked intramembrane
hydrophobic segment) and the peptide 101–126 (intramembrane
hydrophobic segment without CRAC). We obtained corresponding
information by analysing both the peptide-induced changes in the ther-
motropic phase behaviors of the lipid membrane with Chol and the
Chol-induced changes in the environment and structure of the peptides
in the lipid membrane observed by DSC, ﬂuorescence and CD experi-
ments, respectively.
The DSC studies demonstrated that Chol is not miscible with the
DPPC lipid membrane at 15% and 20% mole fraction and the non-
miscibility leads to the compartmentalization of the membrane into
two domains, namely a Chol-rich domain and a Chol-poor domain. In-
corporation of all the caveolin-1 peptides studied here results in a redis-
tribution of Chol in the DPPCmembrane. However, the redistribution of
Chol in the DPPC membrane was different in the presence of different
peptides. In particular, the peptide that contains the CRAC motif
displayed a distinct difference in its affect on the distribution of Chol
in the membrane from the peptide that does not contain the CRAC
motif, as demonstrated by the DSC results of the DPPC/Chol bilayers in
the presence of Cav-1(93–126) and Cav-1(101–126). The formation of
domains was facilitated by the peptide Cav-1(93–126) in the DPPC
membrane with both 15 mol% and 20 mol% Chol, whereas a dispersive
distribution of Chol instead of clustering of Chol in the lipid membrane
was mediated by Cav-1(101–126). The presence of Cav-1(101–126) in
the DPPC membrane was unfavorable for Chol segregation, likely dueTable 5
The phase transition data of DPPC vesicles with varyingmole fractions of Chol in the pres-
ence of Cav-1(101–126) at P:L 1:80.
Chol mol% Tm °C ΔT1/2 °C ΔHt kcal/mol
0 41.4 2.4 6.6
15 39.9 6.7 3.2
20 39.0 6.7 3.2to the non-speciﬁc interaction of the peptide with Chol. In contrast,
there is a speciﬁc interaction of the CRAC-containing peptide with
Chol, which results in the formation of a Chol-rich domain [60]. The dif-
ference between the two peptides in regulating distribution of Chol in
the DPPC membrane suggests the important role of the CRAC motif in
sequestering Chol into domains.
The difference of the peptides in regulating Chol distribution in the
DPPC membrane was also observed in studies of other CRAC-
containing caveolin-1 peptides. Compared with Cav-1(93–126), the
peptide Cav-1(82–101) mediates the membrane partitioning only at a
higher Chol mole fraction (20 mol%) with a smaller ΔTm. At a lower
mole fraction of Chol (15 mol%), the membrane partitioning was not
generated by the addition of Cav-1(82–101) in the DPPC lipids. For the
short peptide Cav-1(94–101), the separation of domains was not ob-
served in the DPPC membrane with both 15 mol% and 20 mol% Chol
at the same P:L ratio (1:80). Only when the P:L ratio was increased to
1:15 the membrane partitioning was mediated by the peptide
Cav(94–101). This suggests that the shorter peptides Cav-1(82–101)
and Cav-1(94–101) have a weaker interaction with Chol than the
intramembrane peptide Cav-1(93–126). In consequence, either greater
quantity of peptide molecules or greater quantity of Chol molecules is
needed for sequestering Chol into domains. Compared with the peptide
Cav-1(94–101), the CSD peptide Cav-1(82–101) was more potent in
mediating tight packing of Chol in the lipid membrane. The differences
among the peptides in mediating Chol segregation reveal that the
intramembrane hydrophobic segment plays an important role in
facilitating the interaction of the CRAC motif with Chol. The segment
in the N-terminal part of the scaffold peptide was also considerably
helpful for targeting of the CRAC motif to Chol, as indicated by the re-
sults showing that the longer peptide Cav-1(82–101) was more potent
in sequestering Chol, albeit less effective than the intramembrane hy-
drophobic segment, compared with the shorter peptide Cav-1(94–
101) in the lipidmembrane containing 20mol% Chol at P:L 1:80. Similar
results were also obtained by R.M. Epand et al. in their study of the pep-
tide Cav-1(83–102) and Cav-1(94–101) in a mixture of SOPC and Chol
[52]. Apparently, the efﬁciency of the CRAC motif in Chol segregation
was augmented by the extension of the sequence to either the N-
terminal part of the CSD or the intramembrane domain. Evaluation of
the secondary structure via CD and ATR-FTIR experiments demonstrat-
ed that the peptides Cav-1(94–101), Cav-1(82–101) and Cav-1(93–
126) adopt predominantly random,β-sheet andα-helix conformations,
respectively. Different conformations of the three peptides in the mem-
branemay be a factor contributing to their different effects on the distri-
bution of Chol in the lipid membrane. It was suggested that a smooth,
uniform surface contour of a transmembrane helix would more readily
mix with a rigid Chol-rich domain [61]. Although the IMD segment of
Cav-1 is proposed to form a helix–break–helix structure [30–32], the in-
teraction of the IMD with Chol by the helical fragments in the hairpin
structure may still be favorable for targeting of the Cav-1 protein to
the Chol-rich domain.
In general, three aspects should be considered for the effects of a
peptide on the distribution of Chol in the DPPC membrane. The ﬁrst is
more favorable interaction of the peptide with Chol than with DPPC
lipids, the second is avoidance of the peptide from interacting with
Chol, and the third is that the peptide neither speciﬁcally favors nor
avoids Chol. Either the ﬁrst or the second factor facilitates the formation
of a Chol-rich domain [60]. In contrast, the third factor may increase
miscibility of Chol with lipids. The thermotropic phase behavior of
DPPC/Chol bilayers in the presence of Cav-1(101–126) shows a pre-
dominant role of the third factor in the distribution of Chol in the lipid
membrane, which leads to an approximately homogeneous distribution
of Chol in the bilayers and fusion of domains. However, the thermotrop-
ic phase behaviors of the DPPC/Chol bilayers in the presence of the
CRAC-containing peptides show a predominant role of the ﬁrst factor
in the distribution of Chol in the lipidmembrane, and, thus, the segrega-
tion of bilayers was promoted. Compared with the lipid distribution in
Fig. 7. Fluorescence spectra of the caveolin-1 peptides (black: wild-type peptides, red: mutants) incorporated with DPPC alone (solid line) or DPPC containing 50 mol% Chol (dot line).
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rich domain in the presence of the CRAC-containing peptide. The in-
volvement ofmore lipids in the Chol-rich domainmakes Cholmolecules
in this domain less tightly packed than they do in the peptide-free
membrane, which could cause the increase in ΔH2 with respect to the
peptide-free bilayers.
The role of Tyr at position 97 of caveolin-1 in the interaction of the
CRAC-containing peptides with Chol was characterized by monitoring
the thermotropic phase behaviors of the DPPC bilayers mixed with
Chol and Y97I mutants. Compared with the wild-type peptides, the
presence of the mutants does not cause an intrinsic change in the
thermotropic phase behaviors of the DPPC/Chol membranes, but onlyFig. 8. Ksv data obtained by acrylamide quenching to Trp residues of the caveolin-1 pep-
tides (black: wild-type peptides, red:mutants) incorporatedwith DPPC alone (fullyﬁlled)
or DPPC containing 50 mol% Chol (ﬁlled with dense line).results in a small increase in PΔH2 and decrease in ΔTm if separation of
endothermic peaks occurs in the DSC thermographs. The fact that the
potency of the peptides in sequestering Chol into domains is only re-
duced and not abolished by the substitution of Ile to Tyr suggests that
the Tyr at position 97 plays a role in the interaction of caveolin-1 with
Chol, but other residue(s) in the CRAC motif may also play a role in
the speciﬁc interaction of the protein with Chol [50]. Nevertheless, a
slightly larger PΔH2 and smaller ΔTm in the presence of themutant pep-
tides than in the presence of the wild-type peptides indicate that the
Chol-rich domain of the DPPC lipid membrane was less tightly packed
in the presence of the mutants than in the presence of the wild-type
peptides likely due to involvement of more lipids in the Chol-rich do-
main in the presence of the mutants.
Theﬂuorescence emission spectra of the Trp residues in the peptides
were used to monitor the distribution of the peptides in the DPPC
lipid vesicles containing 50% mole fraction of Chol. The DPPC bilayers
with 50 mol% Chol are characterized by a liquid-ordered (Lo) phase
[62,63], inwhich hydrocarbon chains of lipids are extended and ordered
as in the gel phase, but the lateral mobility in the bilayer is very high as
in the disordered (Id) phase [64]. The Lo phase is proposed to be more
representative of the membrane organization of caveolae and rafts
[65]. Our results show that the addition of Chol in DPPC vesicles leads
to a decrease in ﬂuorescence intensity and an increase in Ksv for all the
peptides studied. This suggests that the presence of Chol induces a
movement of the peptides in the DPPC lipid membrane from a deeper
position in the absence of Chol to a more solvent exposed position. In-
terestingly, the peptide Cav-1(101–126) that has no CRAC motif
shows a lower magnitude of change either in ﬂuorescence intensity or
in Ksv from the Chol-containing membrane to the Chol-free membrane
than the peptide Cav-1(93–126) that contains the CRAC motif, suggest-
ing that Cav-1(93–126) populates the Chol-rich domain with more
quantity than Cav-1(101–126) and further conﬁrming that the CRAC
motif was critical in the interaction of caveolin-1 peptide segments
with Chol. For the CRAC-containing peptides, either the decrease in
ﬂuorescence intensity or the increase in the acrylamide quenching
Fig. 9. CD spectra of the caveolin-1 peptides (black: wild-type peptides, red: mutants) incorporated with DPPC alone (solid line) or DPPC containing 50 mol% Chol (dot line).
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tides than those for themutants, suggesting that the Trp residues of the
wild-type peptides undergo a more signiﬁcant change in environments
from the Chol-free membrane to the Chol-containing membrane than
those of the mutants, possibly through more preferential interaction
of the wild-type peptides with Chol than the mutants.
The effects of Chol on the secondary structures of the peptides in
DPPC bilayers were also probed by CD and ATR-FTIR measurements.
Although there were some differences in the values from the two
methods possibly due to the differences in the experimental conditions
and spectral treatment methods, comparable conclusions could be
drawn from the two sets of the secondary structure data. In general,
three intramembrane peptides form an α-helical structure. The pres-
ence of Chol resulted in an evident decrease in helicity for Cav-1(101–
126), while the Chol-induced change in helicity of Cav-1(93–126) was
rather small, indicating a role of the CRAC motif in the interaction
with Chol. It seems that the interaction of the CRAC motif with Chol
has an effect of stabilizing helical folding of the IMD peptide in the or-
dered lipid membrane. The Y97I mutation in the CRAC motif results inTable 6
Secondary structure data for the caveolin-1 peptides in pure DPPC and DPPC vesicles with
50 mol% Chol obtained by the CD measurements.
Peptide Chol (mol%) Secondary structure (%)
Helix Strand Turn Unordered
Cav-1(82–101) 0 20 61 4 15
50 5 61 17 17
Cav-1(82–101/Y97I) 0 0 77 8 15
50 9 85 0 6
Cav-1(93–126) 0 77 8 8 7
50 75 10 9 6
Cav-1(93–126/Y97I) 0 69 16 6 9
50 69 7 14 10
Cav-1(101–126) 0 76 9 9 6
50 61 3 36 0a decrease in α-helix folding, which likely occurrs in the CRAC region,
both in the absence and presence of Chol, suggesting that the Y97I
mutation destabilizes the helical structure. Unlike the intramembrane
peptides, the peptide Cav-1(82–101) predominantly adopts a β-sheet
structure and a small amount of helical structure in the pure DPPC
membrane. The helix structure was transferred to the β-strand (CD
result) or β-turn (ATR-FTIR result) by the Y97I mutation, further sug-
gesting a destabilizing effect of the Y97I mutation on helical structure
and the short helical structure may be formed in the CRAC region. The
addition of Chol results in a decrease in the α-helix content for the
wild-type peptide and an increase in the β-strand content for the mu-
tant. This suggests that the presence of Chol in the DPPC membrane is
unfavorable to the α-helix structure, but is favorable to the β-sheet
structure for the scaffolding peptides 82–101. The two 94–101 peptides
were unstructured in the lipidmembrane either with orwithout Chol. It
seems that the formation of the helical structure in the CRAC region of a
wild-type peptide is associated with peptide length and insertion of the
peptide in the membrane.
5. Conclusions
All the CRAC-containing peptides from caveolin-1 in this study
displayed the potential to interact with Chol in the DPPC lipid mem-
brane. The preferential interactions of the CRAC-containing peptides
with Chol could facilitate Chol segregation in the DPPC membrane,
which depends on peptide properties or Chol concentration. The poten-
cy of the CRAC motif in Chol segregation was either signiﬁcantly en-
hanced by the linking with the IMD segment that was inserted into
membrane inner or was enhanced to a less extent by linking of the res-
idues in the CSD N-terminal part which may attach to the
membrane surface. The potency of the CRAC-containing peptides in
Chol segregationwas lowered by theY97Imutation andwas completely
lost by the deletion of the CRAC motif. Different conformations of the
peptides could be a factor that contributes to their different effects on
the distribution of Chol in the lipid membrane.
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